New Findings on Soft Tissue Sarcomas from National Cancer Center Research Institute Summarized (Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System): Oncology – Soft Tissue Sarcomas

2026 JUN 04 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators publish new report on Oncology - Soft Tissue Sarcomas. According to news reporting originating from Tokyo, Japan, by NewsRx correspondents, research stated, “Accurate identification of gene fusions is critical for precision oncological approaches to sarcomas, where specific fusion genes are actionable targets of tyrosine kinase (TK) inhibitors. This study provides a descriptive overview of the real-world use, under a universal health insurance program, of 3 different comprehensive genomic profiling (CGP) panels within the Japanese national CGP system: GenMineTOP, which integrates DNA and RNA sequencing, and 2 DNA-based panels, FoundationOne CDx and the OncoGuide NCC Oncopanel System.”

Our news editors obtained a quote from the research from National Cancer Center Research Institute, “We examined 2,633 sarcoma cases from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database to identify potentially actionable alterations classified by the Cancer Knowledge Database (CKDB). The mean patient age was 51.1 years, and 45% were female. Detection rates of TK fusions (FGFR1-4, NTRK1-3, ALK, RET, ROS1, and BRAF) were compared descriptively. Additionally, 3 sarcoma cases with an NTRK fusion detected by GenMineTOP were functionally validated. Potentially actionable alterations (CKDB Levels A, B, and C) were identified in 566 patients (21.5%). Actionable TK fusions were detected in 3.1% (8 of 254) with GenMineTOP, 1.4% (31 of 2,211) with FoundationOne CDx, and 0.6% (1 of 168) with NCC Oncopanel. GenMineTOP identified rare NTRK fusions, including RBPMS::NTRK2, HTT::NTRK2, and EML4::NTRK3. Functional assays suggested their oncogenic potential and demonstrated responsiveness to the TK inhibitors larotrectinib and entrectinib. In this cohort, the DNA+RNA-based panel showed a higher detection rate for TK fusions, although the panels were applied to different patient groups and the sensitivity and specificity could not be determined. Future studies evaluating different test types on the same tumor specimens are warranted to clarify whether the dual-sequencing approaches can improve the identification of actionable genetic events. Diagnostic Level IV.”

According to the news editors, the research concluded: “See Instructions for Authors for a complete description of levels of evidence.”

This research has been peer-reviewed.

For more information on this research see: Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System. Journal of Bone and Joint Surgery, 2026. Journal of Bone and Joint Surgery can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

The news editors report that additional information may be obtained by contacting Masachika Ikegami, Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan. Additional authors for this research include Satoshi Kamio, Rina Kitada, Satoshi Miwa, Koichi Ogura, Shintaro Iwata, Akira Kawai, Eisuke Kobayashi, Yoshiyuki Suehara and Shinji Kohsaka.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.2106/jbjs.25.01105. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Journal of Bone and Joint Surgery is: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)